Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) Director Sells 2,777 Shares of Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Director Simon Read sold 2,777 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $109.55, for a total transaction of $304,220.35. Following the completion of the transaction, the director owned 2,777 shares in the company, valued at $304,220.35. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Dianthus Therapeutics Stock Down 3.0%

Shares of NASDAQ:DNTH traded down $3.31 during midday trading on Tuesday, hitting $108.49. 777,875 shares of the stock traded hands, compared to its average volume of 972,407. The business’s 50 day moving average is $95.17 and its two-hundred day moving average is $81.36. The stock has a market capitalization of $5.93 billion, a PE ratio of -26.14 and a beta of 1.22. Dianthus Therapeutics, Inc. has a one year low of $19.00 and a one year high of $114.55.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The business had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. As a group, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Truist Financial lifted their price objective on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Wolfe Research reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wall Street Zen raised Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Raymond James Financial reiterated a “strong-buy” rating and issued a $131.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, August 5th. Finally, HC Wainwright upped their price objective on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $124.27.

Institutional Investors Weigh In On Dianthus Therapeutics

Several hedge funds have recently made changes to their positions in DNTH. BlackRock Inc. bought a new position in Dianthus Therapeutics in the second quarter worth $401,990,000. Wellington Management Group LLP boosted its holdings in shares of Dianthus Therapeutics by 3,366.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after buying an additional 2,503,311 shares in the last quarter. Vestal Point Capital LP boosted its holdings in shares of Dianthus Therapeutics by 88.2% during the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after buying an additional 1,499,931 shares in the last quarter. State Street Corp grew its position in shares of Dianthus Therapeutics by 124.7% in the 4th quarter. State Street Corp now owns 1,507,619 shares of the company’s stock worth $62,129,000 after buying an additional 836,571 shares during the period. Finally, Polar Capital Holdings Plc bought a new position in shares of Dianthus Therapeutics in the 3rd quarter worth about $29,434,000. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.